Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2

	Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2
	Sun, SY; Cai, YQ; Song, TZ; Pu, Y; Cheng, L; Xu, HR; Sun, J; Meng, CY; Lin, YF; Huang, HB; Zhao, F; Zhang, SL; Gao, Y; Han, JB; Feng, XL; Yu, DD; Zhu, YL; Gao, P; Tang, HD; Zhao, JC; Zhang, Z; Yang, JM; Hu, ZX; Fu, YX; Zheng, YT; Peng, H
	2021
发表期刊	CELL RESEARCH
ISSN	1001-0602
卷号	31 期号:9 页码:1011-1023
摘要	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global crisis, urgently necessitating the development of safe, efficacious, convenient-to-store, and low-cost vaccine options. A major challenge is that the receptor-binding domain (RBD)-only vaccine fails to trigger long-lasting protective immunity if used alone for vaccination. To enhance antigen processing and cross-presentation in draining lymph nodes (DLNs), we developed an interferon (IFN)-armed RBD dimerized by an immunoglobulin fragment (I-R-F). I-R-F efficiently directs immunity against RBD to DLNs. A low dose of I-R-F induces not only high titers of long-lasting neutralizing antibodies (NAbs) but also more comprehensive T cell responses than RBD. Notably, I-R-F provides comprehensive protection in the form of a one-dose vaccine without an adjuvant. Our study shows that the pan-epitope modified human I-R-F (I-P-R-F) vaccine provides rapid and complete protection throughout the upper and lower respiratory tracts against a high-dose SARS-CoV-2 challenge in rhesus macaques. Based on these promising results, we have initiated a randomized, placebo-controlled, phase I/II trial of the human I-P-R-F vaccine (V-01) in 180 healthy adults, and the vaccine appears safe and elicits strong antiviral immune responses. Due to its potency and safety, this engineered vaccine may become a next-generation vaccine candidate in the global effort to overcome COVID-19.
收录类别	sci
语种	英语
文献类型	期刊论文
条目标识符	http://ir.kiz.ac.cn/handle/152453/13845
专题	科研部门_分子免疫药理学（郑永唐）
推荐引用方式 GB/T 7714	Sun, SY,Cai, YQ,Song, TZ,et al. Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2[J]. CELL RESEARCH,2021,31(9):1011-1023.
APA	Sun, SY.,Cai, YQ.,Song, TZ.,Pu, Y.,Cheng, L.,...&Peng, H.(2021).Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2.CELL RESEARCH,31(9),1011-1023.
MLA	Sun, SY,et al."Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2".CELL RESEARCH 31.9(2021):1011-1023.

条目包含的文件
文件名称/大小	文献类型	版本类型	开放类型	使用许可
2023041163.pdf（252KB）	期刊论文	出版稿	开放获取	CC BY-NC-SA	请求全文